Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06265688 · ClinicalTrials.gov registry record · Phase 1
First In Human Study of CX-2051 in Advanced Solid Tumors
A Phase 1 study of Solid Tumor, Adult, sponsored by CytomX Therapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 160
- Enrollment target
- 4
- Study locations
NCT06265688: Recruiting Phase 1 study of Solid Tumor, Adult, sponsored by CytomX Therapeutics.
NCT06265688 is a Phase 1 study of Solid Tumor, Adult that is actively recruiting participants, run by CytomX Therapeutics. The registered enrollment target is 160 participants, below the 188-participant average among 72 other Solid Tumor, Adult trials with a reported enrollment target (15% lower). The trial reports 4 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06265688, a Phase 1 study of Solid Tumor, Adult, is actively recruiting participants, sponsored by CytomX Therapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 160 participants
- Enrollment target
- 4
- Study locations
Study Summary
The purpose of this first-in-human study, CTMX-2051-101, is to characterize the safety, tolerability, and antitumor activity of CX-2051 as a monotherapy and in combination with bevacizumab in adult participants with advanced solid tumors.
Primary Outcome
The number of participants experiencing a dose-limiting toxicity (DLT) as defined in the protocol, AEs (adverse events), and treatment-emergent adverse events (TEAEs) at any dose level
Conditions Studied
Interventions
- DRUG Bevacizumab
- DRUG CX-2051
Study Locations (4)
Colorado
- Sarah Cannon Research Institute at HealthONE - Denver
Massachusetts
- Dana-Farber Cancer Institute - Boston
North Carolina
- Carolina BioOncology Institute, PLLC - Huntersville
Tennessee
- Sarah Cannon Research Institute, LLC - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 160 participants |
| Start Date | 2024-04-02 |
| Est. Completion | 2029-03-31 |
| Phase | Phase 1 |
What NCT06265688 shows while recruiting
NCT06265688 is an interventional study that assigns participants to a tested intervention. The registered 160 participants enrollment target is mid-sized for trials with a published cap, below the 188-participant average among 72 other Solid Tumor, Adult trials with a reported enrollment target (15% lower).
The record links to 1 condition, with Solid Tumor, Adult appearing as the primary indexed condition, and to 2 interventions - of which Bevacizumab is the first listed.
NCT06265688 reports a single indexed study location in Colorado, Massachusetts, North Carolina.
Frequently Asked Questions
What is clinical trial NCT06265688 about?
NCT06265688 is a clinical study titled "First In Human Study of CX-2051 in Advanced Solid Tumors". The purpose of this first-in-human study, CTMX-2051-101, is to characterize the safety, tolerability, and antitumor activity of CX-2051 as a monotherapy and in combination with bevacizumab in adult participants with advanced solid tumors.
What is the current status of trial NCT06265688?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 160 participants. The study started on 2024-04-02. Estimated completion is 2029-03-31.
What conditions does trial NCT06265688 study?
This clinical trial studies the following conditions: Solid Tumor, Adult.
What interventions are being tested in trial NCT06265688?
The interventions under investigation include: Bevacizumab (DRUG), CX-2051 (DRUG).
Who is sponsoring clinical trial NCT06265688?
This trial is sponsored by CytomX Therapeutics, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06265688 being conducted?
This trial has 4 study locations across Colorado, Massachusetts, North Carolina, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Solid Tumor, Adult
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06265688's enrollment target sits among peer trials
160 28th of 72 higher than 44 of 72 other Solid Tumor, Adult trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Solid Tumor, Adult trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies
RECRUITING · Phase 1
-
Open-Label, Dose-Escalation With Expansion to Assess the Safety, Tolerability, and PK of TRE-515 in Subjects With Solid Tumors
RECRUITING · Phase 1
-
A Study of BI-1206 in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors
RECRUITING · Phase 1
-
Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Study Assessing MTD, Safety, Tolerability, PK and Anti-tumor Effects of LNS8801alone and With Pembrolizumab
RECRUITING · Phase 1
-
A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00501826 · 160 participants · Phase 2
Combination Chemotherapy and Nelarabine in Treating Patients With T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
- NCT00932139 · 160 participants · NA
Effect of Electro-Acupuncture on Blood Pressure
- NCT00992901 · 160 participants · Early Phase 1
Role of Neural and Hormonal Regulation Factors on Insulin Secretion After Gastric Bypass Surgery
- NCT01515527 · 160 participants · Phase 2
Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI